Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision

BACKGROUND/AIMS: To evaluate baseline low-luminance visual acuity (LLVA) as a predictor of visual acuity improvement in patients with neovascular (wet) age-related macular degeneration (wAMD) receiving antivascular endothelial growth factor A (anti-VEGF) therapy. METHODS: In the HARBOR trial, 1084 t...

Descripción completa

Detalles Bibliográficos
Autores principales: Frenkel, Ronald E P, Shapiro, Howard, Stoilov, Ivaylo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975848/
https://www.ncbi.nlm.nih.gov/pubmed/26541435
http://dx.doi.org/10.1136/bjophthalmol-2015-307575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975848/
https://www.ncbi.nlm.nih.gov/pubmed/26541435
http://dx.doi.org/10.1136/bjophthalmol-2015-307575

Ejemplares similares